ArticleMethods in molecular biology (Clifton, N.J.)2026
Utilization of Functional Degradation Pathways for the Characterization of Ubiquitin-Proteasome System Tool Compounds.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitin-proteasome system (UPS) is a highly regulated enzymatic machinery responsible for selective protein degradation, which is an essential process for maintaining cellular proteostasis, signaling, and homeostasis. Dysregulation of the UPS has been implicated in a variety of human diseases, including cancer, neurodegeneration, and inflammatory disorders. Recently, small molecule degraders such as PROTACs and molecular glues emerged that exploit the UPS to selectively degrade disease-associated proteins, and these new modalities are increasingly interesting for drug development and target validation. However, due to the complex multistep pathway, validation of the molecular mechanism of action remains challenging. A number of tool compounds have been developed that can be used to demonstrate that observed PROTAC-induced target degradation relies on the UPS. Despite the availability of these tool compounds, there is no consensus in the community regarding the most appropriate use for these compounds, in particular their dosing and best timepoints used for such functional studies. In this chapter, we present a protocol for the best practice use of UPS-targeting tool compounds to further understand their molecular mechanism of action within the CRBN- and VHL-mediated degradation pathways in human cells. We make use of the HiBiT system supported by a cell viability assay to enable identification of effective, nontoxic concentrations for target degradation rescue experiments. This protocol establishes a framework for performing functional studies and guides the informed, effective use of UPS tool compounds in both research and therapeutic discovery.
Indexed as
Identifiers
42573688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.